Therapies for non-alcoholic steatohepatitis
Liver Research, 2017 Current phase 3 trials for the treatment of non-alcoholic steatohepatitis (NASH) are discussed in this review. Modalities that are based on weight loss include therapeutic lifestyle changes, pharmacological weight loss drugs (e.g., orlistat), and ...
Winston Dunn
doaj +1 more source
A Novel Telescoped Kilogram-Scale Process for Preparation of Obeticholic Acid
Pharmaceutical Fronts, 2021 A novel scalable four-step process has been developed to improve the synthesis of obeticholic acid (OCA). The key step of this process was the isolation of the amide intermediate, which underwent hydrogenation, basic epimerization, ketone reduction, and ...
Cheng-Wei Li +4 more
doaj +1 more source
The role of lipid and lipoprotein metabolism in non-alcoholic fatty liver disease [PDF]
, 2017 Due to the epidemic of obesity across the world, nonalcoholic fatty liver disease (NAFLD) has become one of the most prevalent chronic liver disorders in children and adolescents.
Anania, Caterina +4 more
core +2 more sources
Critical Role of microRNA-21 in the Pathogenesis of Liver Diseases [PDF]
, 2020 MicroRNAs are small non-coding RNAs that range in length from 18 to 24 nucleotides. As one of the most extensively studied microRNAs, microRNA-21 (miR-21) is highly expressed in many mammalian cell types.
Han, Sen +4 more
core +1 more source
Obeticholic acid for the treatment of primary biliary cirrhosis [PDF]
Expert Review of Clinical Pharmacology, 2015 Primary biliary cirrhosis (PBC) is characterized by progressive nonsuppurative destruction of small bile ducts, resulting in intrahepatic cholestasis, fibrosis and ultimately end-stage liver disease. Timely intervention with ursodeoxycholic acid is associated with excellent survival, although approximately one-third of all patients fail to achieve ...
Palak J, Trivedi +2 more
openaire +2 more sources
Fibrates for Primary Biliary Cholangitis: What’s All the Hype?
Annals of Hepatology, 2017 Ursodeoxycholic acid is the first-line therapy for primary biliary cholangitis. However, a subset of patients fail to show biochemical response. For these patients, adjuvant therapies are warranted. Obeticholic acid was conditionally approved as a second-
Cynthia Levy
doaj +1 more source
Managing non-alcoholic fatty liver disease in diabetes: challenges and opportunities [PDF]
, 2017 Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus are two common health problems worldwide. Globally, it has been estimated that a quarter of the adult population in the world currently suffers from NAFLD.1 In Asia, probably ...
Lam, KSL, Lee, CHP
core +1 more source
Farnesoid X receptor (FXR): Structures and ligands
Computational and Structural Biotechnology Journal, 2021 Farnesoid X receptor (FXR) is a bile acid activated nuclear receptor (BAR) and is mainly expressed in the liver and intestine. Upon ligand binding, FXR regulates key genes involved in the metabolic process of bile acid synthesis, transport and ...
Longying Jiang +4 more
doaj +1 more source
Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-assigned Steatosis Grades of Liver Biopsies from Adults with Nonalcoholic Steatohepatitis [PDF]
, 2017 Background & Aims We assessed the diagnostic performance of magnetic resonance imaging (MRI) proton density fat fraction (PDFF) in grading hepatic steatosis and change in hepatic steatosis in adults with nonalcoholic steatohepatitis (NASH) in a multi ...
Bashir, Mustafa R. +15 more
core +1 more source